Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet

(2020) Magdalena M. Bogun et al.   DIABETES CARE

RIPK2 dictates insulin responses to tyrosine kinase inhibitors in obese male mice

(2020) Brittany M Duggan et al.   ENDOCRINOLOGY

Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes

(2020) Laura M. Jacobsen et al.   Diabetes Technology & Therapeutics

Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes

(2020) Teresa Quattrin et al.   NEW ENGLAND JOURNAL OF MEDICINE

State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018

(2019) Nicole C. Foster et al.   Diabetes Technology & Therapeutics

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

(2019) Michael J. Haller et al.   DIABETES

Biomarkers of islet beta cell stress and death in type 1 diabetes

(2018) Emily K. Sims et al.   DIABETOLOGIA

PPARγ Antagonist Gleevec Improves Insulin Sensitivity and Promotes the Browning of White Adipose Tissue

(2016) Sun-Sil Choi et al.   DIABETES

Immunological off-target effects of imatinib

(2016) Laurence Zitvogel et al.   Nature Reviews Clinical Oncology

Elevations in Circulating Methylated and Unmethylated Preproinsulin DNA in New-Onset Type 1 Diabetes

(2015) Marisa M. Fisher et al.   DIABETES

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients

(2015) Mark R. Rigby et al.   JOURNAL OF CLINICAL INVESTIGATION

Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?

(2015) Athanasios Fountas et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Regulation of glucose and lipid homeostasis by adiponectin: Effects on hepatocytes, pancreatic β cells and adipocytes

(2013) Caroline Tao et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

(2013) K. C. Herold et al.   DIABETES

Type 1 diabetes

(2013) Mark A Atkinson et al.   LANCET

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data

(2012) C. J. Greenbaum et al.   DIABETES

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

(2011) Tihamer Orban et al.   LANCET

Plasma Adiponectin Levels Are Markedly Elevated in Imatinib-Treated Chronic Myeloid Leukemia (CML) Patients: A Mechanism for Improved Insulin Sensitivity in Type 2 Diabetic CML Patients?

(2010) Stephen Fitter et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Imatinib Mesylate Reduces Endoplasmic Reticulum Stress and Induces Remission of Diabetes in db/db Mice

(2009) M. S. Han et al.   DIABETES

Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of Onset

(2009) E. Ferrannini et al.   DIABETES

Tyrosine kinases as targets for the treatment of rheumatoid arthritis

(2009) Christina D'Aura Swanson et al.   Nature Reviews Rheumatology

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

(2009) Mark D. Pescovitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice

(2008) C. Louvet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet

(2007) Robert Hägerkvist et al.   CLINICAL SCIENCE